Navigation Links
NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
Date:9/2/2008

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer, and Kevin O'Boyle, Executive Vice President and Chief Financial Officer, are scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference at the Grand Hyatt New York Hotel on Tuesday, September 9, 2008, at 8:35 a.m. ET.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NuVasive Completes Acquisition of Osteocel Biologics Business
2. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
3. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
4. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
5. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
8. NuVasive to Host Investor Reception on September 11, 2007
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
(Date:12/17/2014)... New York, NY (PRWEB) December 16, 2014 ... undergone significant changes since 2013, which is why IBISWorld ... one, this industry continues to benefit from an intensified ... 2014, the proposal for new emission standards for power ... affected industry operators. According to IBISWorld Industry Analyst Sarah ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 8 SuperGen, Inc.,(Nasdaq: SUPG ), a ... commercialization of therapies for solid tumors and,hematological malignancies, ... Michael V. McCullar, Ph.D., Vice President of Drug,Discovery ... 5th,Annual Investor Summit on Monday, September 15, 2008 ...
... (Nasdaq: HGSI ) announced today that its presentation ... will be webcast and,may be accessed at http://www.hgsi.com ... member of Human Genome Sciences, senior management team will ... 10:15 am Eastern,Time., Investors interested in listening to ...
... Presented at the 7th International ... Symposium on Uveitis in Germany, ... antibody fragment therapeutics, today announced that the,company has successfully completed ... ESBA105, in ophthalmic indications. In,April 2008, ESBATech initiated the Phase ...
Cached Biology Technology:SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/12/2014)... BEACH GARDENS, Fla. , Nov. 12, 2014 /PRNewswire/ ... solutions, announced today that its U.are.U ® fingerprint ... retail bakery chain in Central Mexico ... in June 2014 to eliminate payroll issues caused by ... Prior to installing the U.are.U fingerprint readers, Montparnasse relied ...
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... capacity to buffer against climate change? As one ... takes up roughly one-third of all human carbon emissions, ... But whether the ocean can continue mopping up ... in the air. Previous studies on the topic have ...
... of Houston researcher is an author on a landmark ... form of ovarian cancer that is published in the ... Ovarian cancer is the fifth-leading cause of cancer death ... study, which was conducted by The Cancer Genome Atlas ...
... compounds that can be highly contaminant. They are found, ... pharmaceutical industries and in waters polluted by ships, fuel. ... the impact of PAHs on a number of media, ... up the methodology, prepared it for the pertinent circumstances ...
Cached Biology News:Climate change reducing ocean's carbon dioxide uptake 2Climate change reducing ocean's carbon dioxide uptake 3University of Houston researcher an author of multi-institutional genetic study of ovarian cancer 2University of Houston researcher an author of multi-institutional genetic study of ovarian cancer 3Determining pollution level of a medium without wasting tools, time or solvents possible 2Determining pollution level of a medium without wasting tools, time or solvents possible 3
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: